Skip to content
ApplyGive

Other ways to search: Events Calendar | UTHSC News

Evan S. Glazer, MD, PhD, FACS

Evan S. Glazer, MD, PhD, FACS
  • Assistant Professor of Surgery
  • Principal Investigator, Center for Cancer Research

Specialties: Surgical Oncology

Clinical Expertise:

    • Minimally invasive HBP surgery
    • Basic and clinic research
    • Management of pancreatic tumors and cysts
    • Management of liver tumors
    • GI malignancies
Contact

Asia Dugger
Administrative Aide
P: 901.448.3011
F: 901.448.1498

New Patient
P: 901.516.0792

UTHSC
910 Madison Ave.
Suite 325
Memphis, TN 3863

UT Methodist - Surgical Oncology
1211 Union Ave.
Suite 300
Memphis, TN 38104

Evan S. Glazer, MD, PhD, FACS  is an Assistant Professor in the Division of Surgical Oncology, Department of Surgery, at The University of Tennessee Health Science Center.  He is a researcher and principal investigator in Center for Cancer Research as well. Dr. Glazer clinical and research focus is on pancreatic, liver, and biliary tract malignancies including multi-disciplinary care, clinical trials, and basic science research. He manages advanced, multi-disciplinary algorithms to maximize, optimize, and personalize therapies for each patient including surgery, radiation, and chemotherapy. He is double board certified in complex surgical oncology and general surgery.

Dr. Glazer is a surgeon scientist who works with experts in surgical oncology, medical oncology, and radiation oncology in both the clinic and the laboratory. He is well published and has received numerous grants for ongoing research projects including a Career Development Award.  His primary research investigates the pancreatic cancer immune tumor microenvironment and the role of TGF-b in pancreatic cancer progression. He is site principal investigator for 2 clinical trials and treated the first patient on the ALIGN trial for intrahepatic cholangiocarcinoma (bile duct cancer in the liver).

Dr. Glazer is a member of the American College of Surgeons, Society of Surgical Oncology, Association for Academic Surgery, and the American Society of Clinical Oncology. He is a content expert and serves on national committees for the Society for Surgery of the Alimentary Tract, Society of Surgical Oncology, and the Association for Academic Surgery.

Medical School

  • George Washington University School of Medicine, Washington, DC

Residency

  • Department of Surgery, University of Arizona, Tucson, AZ

Fellowships

  • Research: NIH T32 Surgical Oncology, MD Anderson Cancer Center, Houston TX
  • Clinical: Surgical Oncology, Moffitt Cancer Center, University of South Florida, Tampa, FL

Graduate School

  • MPH in Epidemiology, George Washington University, Washington, DC
  • PhD in Cancer Biology, University of Arizona, Tucson, AZ

Professional Organizations

  • American College of Surgeons, Associate Fellow
  • American Association for Cancer Research
  • Society of Surgical Oncology
  • Association for Academic Surgery
  • American Society of Clinical Oncology
  • The Society for Surgery of the Alimentary Tract

Board Certifications

  • American Board of Surgery - General Surgery
  • American Board of Surgery - Complex General Surgical Oncology

Dr. Glazer is a principal investigator at UTHSC and Methodist University Hospital for 2 international clinical trials investigating high intensity liver directed chemotherapy.  He is an active basic and translational science investigator in Cancer Research Building as part of the Center for Cancer Research at UTHSC.  His long-term research goals are to understand the effects of TGF-b in pancreatic cancer progression, the role of TGF-b in modulating the immune system around the tumor, and the critical proteins involved in pancreatic cancer progression to develop effective therapies. Dr. Glazer and his team use a variety of tools and models to perform research through collaborations with a number of investigators at UTHSC and St. Jude.

Dr. Glazer has published over 50 peer reviewed articles in elite journals including the Journal of Clinical Oncology, Journal of the American College of Surgeons, Cancer, Clinical Cancer Research, Cancer Prevention Research, and OncoTarget.
 
  • Alvarez MA, Freitas JP, Mazher Hussain S, Glazer ES. TGF-β Inhibitors in Metastatic Pancreatic Ductal Adenocarcinoma. J Gastrointest Cancer. 2019 Jun;50(2):207-213. doi: 10.1007/s12029-018-00195-5. Review. PubMed PMID: 30891677.

  •  Hussain SM, Reed LF, Krasnick BA, Miranda-Carboni G, Fields RC, Bi Y, Elahi A, Ajidahun A, Dickson PV, Deneve JL, Hawkins WG, Shibata D, Glazer ES. IL23 and TGF-ß diminish macrophage associated metastasis in pancreatic carcinoma. Sci Rep. 2018 Apr 11;8(1):5808. doi: 10.1038/s41598-018-24194-5. PubMed PMID: 29643359; PubMed Central PMCID: PMC5895618.

  • Ferguson MD, Dong L, Wan J, Deneve JL, Dickson PV, Behrman SW, Shibata D, Martin MG, Glazer ES. Molecular Alterations Associated with DNA Repair in Pancreatic Adenocarcinoma Are Associated with Sites of Recurrence. J Gastrointest Cancer. 2019 Jun;50(2):285-291. doi: 10.1007/s12029-018-0073-8. PubMed PMID: 29427136.

  • Glazer ES, Zager JS. Chemosaturation With Percutaneous Hepatic Perfusion in Unresectable Hepatic Metastases. Cancer Control. 2017 Jan;24(1):96-101. Review. PubMed PMID: 28178721.

  • Glazer ES, Rashid OM, Klapman JB, Harris CL, Hodul PJ, Pimiento JM, Malafa MP. Endoscopic ultrasonography complements computed tomography in predicting portal or superior mesenteric vein resection in patients with borderline resectable pancreatic carcinoma. Pancreatology. 2017 Jan - Feb;17(1):130-134. doi: 10.1016/j.pan.2016.12.001. Epub 2016 Dec 5. PubMed PMID: 28043760.

  • Glazer ES, Welsh E, Pimiento JM, Teer JK, Malafa MP. TGFβ1 overexpression is associated with improved survival and low tumor cell proliferation in patients with early-stage pancreatic ductal adenocarcinoma. Oncotarget. 2017 Jan 3;8(1):999-1006. doi: 10.18632/oncotarget.13533. PubMed PMID: 27895310; PubMed Central PMCID: PMC5352213.

  • Glazer ES, Zhang HH, Hill KA, Patel C, Kha ST, Yozwiak ML, Bartels H, Nafissi NN, Watkins JC, Alberts DS, Krouse RS. Evaluating IPMN and pancreatic carcinoma utilizing quantitative histopathology. Cancer Med. 2016 Oct;5(10):2841-2847. doi: 10.1002/cam4.923. Epub 2016 Sep 26. PubMed PMID: 27666740; PubMed Central PMCID: PMC5083737.

  • Glazer ES, Rashid OM, Pimiento JM, Hodul PJ, Malafa MP. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma. Surgery. 2016 Nov;160(5):1288-1293. doi: 10.1016/j.surg.2016.04.039. Epub 2016 Jul 20. PubMed PMID: 27450715; PubMed Central PMCID: PMC5086285.

  • Glazer ES, Amini A, Jie T, Gruessner RW, Krouse RS, Ong ES. Recognition of complications after pancreaticoduodenectomy for cancer determines inpatient mortality. JOP. 2013 Nov 10;14(6):626-31. doi: 10.6092/1590-8577/1883. PubMed PMID: 24216548.

  • Glazer ES, Hornbrook MC, Krouse RS. A meta-analysis of randomized trials: immediate stent placement vs. surgical bypass in the palliative management of malignant biliary obstruction. J Pain Symptom Manage. 2014 Feb;47(2):307-14. doi: 10.1016/j.jpainsymman.2013.03.013. Epub 2013 Jul 3. Review. PubMed PMID: 23830531; PubMed Central PMCID: PMC4111934.
 

For Full Listing: Evan S. Glazer, MD, PhD, PubMed Publications

May 26, 2022